INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.260
-0.090 (-6.67%)
Jun 5, 2026, 4:00 PM EDT - Market closed
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,981,000
Market Cap
33.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Boundless Bio | 28 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| Lisata Therapeutics | 21 |
| ABVC BioPharma | 19 |
INMB News
- 3 days ago - INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial - TheFly
- 3 days ago - INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - GlobeNewsWire
- 4 days ago - INmune Bio Slides: Corporate presentation - Filings
- 21 days ago - INmune Bio publishes MINDFuL trial results in NPJ Dementia - TheFly
- 21 days ago - INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - GlobeNewsWire
- 22 days ago - INmune Bio receives fast track designation from FDA for XPro - TheFly
- 22 days ago - INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - GlobeNewsWire
- 23 days ago - INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point - GlobeNewsWire